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Abstract
Introduction—In the absence of an HIV vaccine or cure, antiretroviral (ARV) based prevention 
strategies are being investigated to reduce HIV incidence. These prevention strategies depend on 
achieving effective drug concentrations at the site HIV exposure which is most commonly the 
mucosal tissues of the lower gastrointestinal tract and the female genital tract.
Areas covered—This article collates all known data regarding drug exposure in these 
vulnerable mucosal tissues, and reviews important mechanisms of ARV drug distribution. 
Research papers and abstracts describing antiretroviral pharmacokinetics in the female genital 
tract and lower gastrointestinal mucosal tissues available in MEDLINE® or presented at scientific 
conferences prior to December 2014 are reviewed in detail. Important influences on ARV mucosal 
tissue distribution, including protein binding, active drug transport, and endogenous hormones, are 
also reviewed.
Expert opinion—ARVs exhibit highly variable pharmacokinetics in mucosal tissues. In general, 
antiretroviral exposure is higher in the lower gastrointestinal tract compared to the female genital 
tract, but concentrations required for protective efficacy are largely unknown. The expected site of 
HIV exposure represents an important consideration when designing and optimizing antiretroviral 
based prevention strategies.
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1. Introduction
As of the end of 2013, 35 million people worldwide were living with HIV/AIDS.(1) Highly 
active antiretroviral treatment (HAART) strategies effectively control HIV's progression into 
AIDS, restoring life expectancy and quality of life to that of an uninfected person. 
Nonetheless, of the 32.6 million HIV infected persons living in lower and middle-income 
countries, approximately 64% (20.9 million) do not have access to HAART.(1) Therefore, 
prevention strategies are needed to contain the epidemic.
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In the absence of a licensed vaccine, the use of antiretrovirals for HIV prevention has been 
investigated. The utility of one of these approaches, treatment as prevention (TasP), was 
recently established in the landmark HPTN052 study where it was found that consistent 
suppression of blood plasma HIV RNA in HIV infected subjects using early HAART 
reduced transmission to their uninfected partners by greater than 95%.(2) This study 
demonstrated the highest degree of protection of any HIV prevention trial. In the United 
States, less than 50% of HIV infected patients on HAART exhibit a suppressed viral load.(3) 
This is an important limitation of the TasP approach and warrants further exploration into 
alternative HIV prevention strategies in uninfected individuals.
In 2012, Truvada®, a fixed dose combination tablet of two nucleoside reverse transcriptase 
inhibitors tenofovir disoproxil fumarate and emtricitabine, received FDA approval to be 
used as part of an HIV prevention package in high risk individuals. Truvada® received this 
licensing on the basis of a 44-75% decrease in HIV incidence in 3 clinical trials studying its 
use in diverse study populations including: serodiscordant heterosexual couples (Partner's 
PrEP) and other high risk heterosexual individuals (TDF2), and men who have sex with men 
(MSM; iPrEX).(4-6) Subsequently, a study investigating Truvada® pre exposure 
prophylaxis (PrEP) in IV drug users demonstrated 49% protection.(7) Truvada® is the first 
relatively discreet, user-controlled HIV prevention option available to women. Yet, clinical 
trials in women have exhibited mixed results: two large phase III trials, FEM-PrEP and 
VOICE, failed to show HIV prevention efficacy for tenofovir taken with or without 
emtricitabine.(8, 9) These results were explained by the low degree of adherence to the daily 
regimens by study subjects. Subsequently, observational analyses have directly linked the 
effectiveness of Truvada® for PrEP with adherence.(10, 11) However, the degree of 
adherence required for protection may be contingent on the site of HIV exposure as 
evidenced by recent data demonstrating only two doses per week of Truvada® reduced HIV 
incidence by up to 90% in the MSM population of iPrEX (10): a level of adherence that was 
also seen in FEM PrEP and VOICE.(8, 9)
The most common mode of HIV transmission is through sexual activity, whereby mucosal 
tissues are the primary sites of HIV exposure. For TasP approaches to be successful, drug 
concentrations in infected individuals must be sufficient to suppress viral replication and 
shedding in the local anatomical sites associated with transmission, and may be necessary at 
high concentrations in the mucosal fluid serving as the viral source of transmission.(12) 
Conversely, PrEP approaches rely on drug concentrations in an uninfected individual being 
sufficient to prevent viral entry, integration or replication in HIV target cells in mucosal 
tissue and/or regional lymph nodes at the time of exposure.(13) Consequently, when 
considering the utility of TasP and PrEP for global reduction in HIV incidence, a thorough 
understanding of antiretroviral pharmacology in mucosal tissues becomes exceedingly 
important to ensure that optimal drugs, doses, and dosing schedules have been selected. For 
this purpose, the present review will examine antiretroviral pharmacokinetics in the mucosal 
tissue types most commonly involved in HIV transmission –the lower gastrointestinal tract 
and the female genital tract.
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Research papers and abstracts describing antiretroviral pharmacokinetics in the female 
genital tract and lower gastrointestinal mucosal tissues published in the MEDLINE® 
database from January 2000 to December 2014 were identified using the following search 
terms: HIV, antiretroviral, pharmacokinetics, cervicovaginal fluid, cervical tissue, vaginal 
tissue, cervix, vagina, rectal fluid, rectal tissue, and rectum. Individual drug names were also 
included in the search terms. All original articles and relevant reviews discussing 
antiretroviral concentrations in the mucosal fluid or tissue of the gastrointestinal and female 
genital tract for any commercially available antiretrovirals or antiretroviral currently under 
investigation were reviewed in detail. Abstracts presented at scientific conferences prior to 
December 2014 were also included in this review.
3. Mucosal Tissue Pharmacokinetic Considerations
Mucosal tissues represent a particularly dynamic microenvironment which is subject to a 
number of regulatory pathways including paracrine, autocrine and endocrine signaling. 
Understanding the pharmacologic factors guiding drug distribution and how these are 
regulated within the tissue compartment is important for interpreting mucosal tissue 
pharmacokinetic data. In the subsections below, we describe three of these factors: protein 
binding, membrane drug transporter activity, and endogenous hormones.
3.1 Protein Binding
Protein binding is an important consideration in the pharmacokinetic profile of 
antiretrovirals, because only the unbound fraction (ie free drug) is available for 
pharmacologic activity. The extent of protein binding may affect a compound's ability to 
exit the vasculature and penetrate into the interstitial tissue space.(14) The primary proteins 
responsible for binding antiretrovirals are albumin and α1 acid glycoprotein (AAG).(15) 
The extent of binding to these proteins is highly variable amongst the antiretroviral classes.
(16) For instance, most protease inhibitors are more than 90% bound to AAG; while the 
non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz is more than 99% bound 
to albumin.(16) Importantly, the concentration of albumin and AAG are much lower in 
mucosal fluid relative to blood plasma. In one investigation of cervical mucus, the mean 
(SD) concentration of albumin and AAG was 73 (45) and 6.6 (3.6) mg/L, respectively. Both 
of these values are less than 1% of the concentration found in blood plasma.(17) For one 
antiretroviral, maraviroc, protein binding is reduced 10-fold in the female genital tract: from 
approximately 76% in blood plasma to approximately 7.6% in cervicovaginal secretions.(18, 
19) These findings imply that a higher degree of pharmacologic activity might be achieved 
in mucosal fluid relative to plasma given the same total drug concentration in the two 
matrices.
Alteration in protein binding can affect pharmacodynamic markers such as the 50% 
inhibitory concentration (IC50), and confound pharmacokinetic (PK)/pharmacodynamic 
(PD) analyses that extrapolate inhibitory quotients (the ratio between drug concentration at 
the end of the dosing interval and level of drug resistance of the viral isolate), to clinical trial 
data.(16) For example, the protease inhibitor SC-52151 failed to show a clinical effect 
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despite achieving an adequate concentration in the plasma.(20) This was later shown to be 
due to AAG binding, which reduced the activity of the drug by 17-fold in MT-2 cells.(21) 
Kempf et al. found that by including just 10% fetal calf serum in cell culture media, 
lopinavir was 96% protein bound, thus providing proof of concept for in vitro manipulation 
to produce better pharmacodynamic estimates.(22) A recent in vitro investigation in CD4+ T 
cells isolated from peripheral blood mononuclear cells (PBMCs) found that increasing the 
extracellular concentration of human serum albumin (HSA) from 1 to 80 mg/mL resulted in 
reduced intracellular concentrations of approximately 8-fold for efavirenz (at a 
concentration of 5ng/mL), 1.7-fold for raltegravir (at a concentration of 5ng/mL), and 2.3-
fold for etravirine (at a concentration of 2ng/mL).(23) Thus careful consideration of the 
extent to which a drug is protein bound is critical for translating in vitro data into the in vivo 
system.
3.2 Drug Transporters
Transporter proteins are located on cell membranes of tissues such as the colorectal and 
genital tract mucosa, and are highly involved in the uptake and efflux of drugs. Several 
antiretrovirals are substrates of drug transporters within the ATP binding cassette (ABC) and 
solute carrier (SLC) families.(24) Recent efforts have been directed at elucidating the role of 
mucosal tissue transporters in the distribution of drugs to the female genital and lower 
gastrointestinal tracts. Zhou et al. investigated the mRNA expression of several ABC efflux 
transporters as well as SLC and SLCO uptake transporters in human vaginal and 
ectocervical tissue.(25) Liver tissue was used as a reference standard due to abundant 
expression of the drug transporters investigated.(26) The efflux transporters MRP1 and 
MRP4 were highly expressed (50-100% of reference tissue) in cervicovaginal tissue, while 
MRP2 and the uptake transporters, OAT1 and OAT3, were less than 2% of the reference 
tissue. This analysis didn't include information regarding location of these transporters 
within the epithelium, which is important to interpret the data correctly. For instance, 
abundant expression of efflux transporters in the squamous epithelium adjacent to the lumen 
would increase elimination of drug substrates from the tissue. However efflux transporters 
located within the basal lamina (the most interior layer of the epithelium), would increase 
transport into the squamous epithelial layer and lead to accumulation of drug substrates.
Nicol et al. addressed this by quantifying the mRNA and protein expression of 3 efflux 
(MDR1, MPR2, MRP4) and 3 uptake (OAT1, OAT3 and OATP1B1) transporters in 
cervical, vaginal, and colorectal tissue using Real-Time PCR and immunohistochemistry 
techniques.(27) Zhou's findings agree with Nicol's analysis which revealed consistent 
expression of the ABC transporters at different levels in each tissue type. MDR1 and MRP2 
mRNA expression in female genital mucosal tissue was found to be 3 to 4-fold higher than 
colorectal tissue (p<0.001). Conversely, MRP4 mRNA in colorectal tissue was 2-fold higher 
than female genital mucosal tissue (p<0.05). While diffuse MDR1 protein expression was 
seen throughout the vaginal and ectocervical tissue, expression appeared to be localized to 
the luminal surface in endocervical and colorectal tissue. Diffuse MRP2 protein expression 
was observed in the epithelia of all tissue types. Finally, MRP4 protein expression appeared 
diffuse throughout the vaginal squamous epithelium and colorectal columnar epithelium. 
However, positively stained lymphocytes and monocytes appeared to be localized to the 
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luminal surface of the colorectal epithelium. The influx transporters OAT1, OAT3, and 
OAT1B1, exhibited a lower degree of expression in all tissues compared with efflux 
transporters: <25% of all mucosal tissue samples exhibited quantifiable expression and all 
detectable tissue samples were <0.1% of expression compared to kidney tissue (used as a 
reference due to its abundant expression of uptake transporters).(26, 27) These data suggest 
that efflux transporters (MDR1, MRP2, and MRP4) play a role in drug distribution in female 
genital and colorectal tissues.
Table 1 summarizes the drug transporter affinity for available antiretrovirals. Recent 
modeling work has determined that being a substrate of MRP1 positively correlates with 
female genital tract tissue concentrations; whereas being a substrate for MRP4 negatively 
correlates with tissue concentration.(28) The negative correlation between tissue penetration 
and MRP4 substrate status is in support of the findings that MRP4 expression appears 
diffuse throughout the female genital tract thus decreasing accumulation in the tissue.
Finally, the expression of efflux transporters appears to be regulated by inflammatory 
cytokines released in response to infection or injury.(29, 30) Pro-inflammatory mediators 
like IL-6, IL-1β and INF-γ have been shown to decrease the expression of BCRP and 
MDR1(30-32). Since mucosal inflammation may be consequence of HIV infection(33), it is 
possible that stage of HIV infection may influence antiretroviral drug distribution. 
Investigation with the antibiotic linezolid (an MDR1 substrate) has shown altered exposure 
in soft tissues correlated with degree of inflammation.(34) However, the effect of local 
inflammation on antiretroviral drug distribution to mucosal tissues is yet to be determined.
3.3 Endogenous Hormones
Another important consideration is the effect of endogenous hormones on drug distribution 
to mucosal tissues. Hormonal and physiological variations occurring during the follicular, 
ovulatory and luteal phases of the menstrual cycle may alter certain pharmacokinetic 
parameters such as protein binding and oxidative hepatic metabolism.(35) In cultured 
epithelial cells of the female genital tract, estradiol and progesterone were found to regulate 
the intracellular concentration of tenofovir diphosphate.(36) Additionally, MDR1 expression 
in the female genital mucosa appears to be subject to hormonal regulation with highest 
expression correlating with the luteal phase of the menstrual cycle(37) and lowest 
expression in postmenopausal women.(27) However, the literature describing the clinical 
implications of these physiological alterations for antiretrovirals is extremely limited. Sheth 
et al. investigated trough cervicovaginal concentrations of tenofovir, emtricitabine, and 
atazanavir in 20 HIV infected women and found no correlation between cervicovaginal fluid 
concentration and menstrual cycle.(38) Likewise, cervical raltegravir trough concentrations 
in 9 healthy volunteers demonstrated no correlation with phase of menstrual cycle.(39) 
However, the extensive between-subject variability in raltegravir cervical tissue 
concentrations (coefficient of variation=195.7%) makes it difficult to conclude that 
menstrual cycle does not impact drug distribution to the female genital tract. No 
investigation to date has explored the impact of hormonal changes on drug distribution 
within the colorectal tissue.
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4. Mucosal Tissue Pharmacokinetics
The distribution of antiretroviral agents has been widely investigated in the female genital 
tract by measuring drug concentrations in cervicovaginal fluid. Cervicovaginal fluid allows 
for more intensive pharmacokinetic sampling within individuals and overcomes some of the 
challenges posed by tissue biopsies. Distribution of antiretrovirals in the mucosal fluid of the 
lower gastrointestinal tract has not been widely studied. One study that measured drug 
concentration of dolutegravir in rectal fluid found that self-collected rectal fluid swabs were 
an unreliable surrogate for drug exposure in the rectal tissue because of large within- and 
between-subject variability.(40)
When evaluating mucosal tissue pharmacokinetics, a ratio between drug exposure in the 
compartment relative to drug exposure in the blood plasma is commonly calculated to 
correct for plasma drug exposure with different drug combinations and dosing strategies. 
The ratio can be calculated with either single sampling times or by area under the 
concentration time curve (AUC). Utilizing the AUC approach minimizes spurious results 
due to lag times in distribution to peripheral compartments. Figure 1 reports the penetration 
ratios for each antiretroviral in the female genital or lower gastrointestinal tissue and 
includes ratios derived with AUCs (when available) or concentrations at the end of the 
dosing interval (Ctau). A summary table of the methods and results of antiretroviral 
pharmacokinetic studies in the female genital mucosal tissues up to 2011 can be found in a 
review by Else and colleagues.(41)
4.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination NRTIs form the backbone of most HIV treatment regimens. These agents 
require intracellular phosphorylation to their active metabolites, which compete with the 
host's endogenous nucleotides for incorporation into the elongating proviral DNA strand. In 
general, agents within this class exhibit a low degree of protein binding (<50%) and hepatic 
biotransformation.(42) Upon phosphorylation the intracellular active moieties are trapped 
within the cell membrane, and only parent compounds are readily detectable in extracellular 
fluid spaces such as blood plasma, cervicovaginal fluid, and seminal plasma. Currently one 
of the most commonly used NRTIs, tenofovir, is being investigated for PrEP in a 1% gel 
formulation. This section will review the mucosal tissue pharmacokinetics of orally and 
topically administered NRTIs.
Dumond et al first described the median (IQR) cervicovaginal fluid to blood plasma 
AUC0-tau ratios following single and multiple doses of 7 NRTIs in HIV infected patients 
initiating or changing antiretrovirals for HIV treatment. These are listed by rank order for 
the single dose in Table 2. Following the single dose, all agents were detected in 
cervicovaginal fluid within 4 hours and reached peak concentrations within 6 hours 
following a single dose.(43) Of the NRTIs only the older agents, didanosine and stavudine, 
exhibited cervicovaginal fluid to blood plasma ratios of less than 20%. Subsequently, 
tenofovir and emtricitabine were shown to exhibit 2-26 times higher cervicovaginal fluid 
exposure compared to blood plasma exposure when measured after a single dose over 14 
days. The terminal half-life in plasma was estimated to be 47 hours for tenofovir and 49 
hours for emtricitabine, and in cervicovaginal fluid, it was estimated to be 71 hours for 
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tenofovir and 40 hours for emtricitabine.(44) Since these half-lives are similar to previously 
published emtricitabine triphosphate (FTCtp) and tenofovir diphosphate (TFVdp) data(45), 
this extended elimination phase was thought to reflect clearance and dephosphorylation of 
intracellular FTCtp and TFVdp.
The formation of TFVdp and FTCtp have been well characterized in the female genital tract 
following a single dose.(44, 46, 47) The most recent of these studies measured parent and 
intracellular concentrations at multiple time points over 48 hours across a 4-fold dosing 
range (150 to 600mg for tenofovir disoproxil fumarate and for 100 to 400mg emtricitabine).
(46) While the time to peak concentrations (Tmax) of tenofovir and emtricitabine is 
achieved within 6 hours in cervical and vaginal tissues, the formation of the active 
metabolites are delayed, with a median Tmax of 24 hours for TFVdp and 12 hours for 
FTCtp.(46) Although TFVdp was detected in vaginal tissue for up to 14 days following a 
single fixed dose combination tablet of tenofovir disoproxil fumarate 300mg and 
emtricitabine 200mg, FTCtp was only detected for up to 2 days.(44) Louissaint et al. 
confirmed the persistence of TFVdp in vaginal tissue after a single dose, and calculated a 
terminal half-life of 53 hours.(47) This tissue half-life is consistent with TFVdp's 49.7 hour 
in vitro half-life in resting PBMC cultures.(45)
Multiple pharmacokinetic investigations suggest differential distribution of tenofovir and 
emtricitabine between mucosal tissues types, which has important implications for 
antiretroviral based prevention strategies. Pharmacokinetic analysis investigating exposure 
at 6 to 48 hours following a single dose found 10-fold higher TFVdp exposure in colorectal 
tissue compared to female genital mucosal tissue.(46) However, FTCtp was 170 times 
higher in the female genital mucosal tissue compared to the rectal tissue. When these 
compounds were measured over 14 days following a single dose, tenofovir and TFVdp 
rectal tissue AUC0-14days remained were 60-100 times higher than female genital tract 
tissue.(44, 47) The difference in the concentration gradient between these two studies is 
likely due to the delayed accumulation of TFVdp in rectal tissue (median Tmax≥48 hours) 
compared to female genital tract tissue (median Tmax=24 hours).(46) Emtricitabine and 
FTCtp AUC0-14days were approximately 10 times higher in female genital tract tissue than 
colorectal tissue.(44)
Topical tenofovir 1% gel has been investigated for application in both the female genital 
tract and the colorectum. Once instilled, TFVdp can be detected in tissues within 0.5 hours.
(48, 49) A randomized cross-over PK study found that a 40mg dose of topical tenofovir in 
the vagina achieved more than a 100-fold higher tenofovir and TFVdp concentrations in 
vaginal and cervical tissue compared to the standard 300mg oral dose.(50) Maximum blood 
plasma concentrations following daily vaginal application of the gel was approximately 1% 
of the maximum concentration (Cmax) following daily oral tenofovir 300mg (median 
Cmax=3.9 vs 332ng/mL, respectively). Thirty minutes after application, a separate study 
found that the gel yielded TFVdp concentrations in colorectal tissue 6 times higher than 
concentrations achieved after an oral dose(49) Maximum blood plasma concentrations 
following 7 daily rectal administrations of the gel were ∼3% of the exposure following a 
single dose of oral tenofovir 300mg (median Cmax=8.61 vs 252ng/mL). Rectal 
administration also led to detectable tenofovir concentrations in vaginal fluid: vaginal fluid 
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Cmax was approximately 2.5 logs lower than colorectal fluid but approximately 2-fold 
higher compared to vaginal fluid Cmax following oral dosing.(51)
4.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
The NNRTIs constitute several first line antiretroviral therapies in combination with NRTIs. 
By binding non-competitively to the reverse transcriptase enzyme, they inhibit transcription 
of viral RNA. Delavirdine, efavirenz and nevirapine are first generation NNRTIs while 
rilpivirine and etravirine are second generation. The penetration of most NNRTIs into the 
female genital tract is limited.(14) In a study by Min et al. cervicovaginal fluid:blood plasma 
ratios were 0.83 for nevirapine, 0.48 for delavirdine, and < 0.08 for efavirenz.(52) These 
penetration ratios demonstrate an inverse relationship with the degree of protein binding 
exhibited by each agent (nevirapine=60% bound, delavirdine=98% bound, and 
efavirenz≥99.5%).(53-55) The penetration of these agents into the colorectal tissue has not 
been studied.
In the DIVA02 study of 12 HIV-1 infected women, the etravirine median (IQR) 
cervicovaginal fluid:blood plasma ratio was 1.2 (0.5-4.8).(56) Despite high (99%) protein 
binding, etravirine's low molecular mass and lipophilic structure may be responsible for the 
increased mucosal tissue penetration. A separate study in 12 HIV-negative men determined 
that after a single dose of etravirine, rectal tissue exposure was ∼15-fold higher than blood 
plasma: with repeated dosing, rectal tissue exposure was ∼9-fold higher.(57)
The pharmacokinetics of oral rilpivirine have not been investigated in mucosal tissues. 
However, interest has grown for the long acting parenteral formulation of the drug, both for 
PrEP and to increase adherence in HIV treatment. Mucosal distribution with this formulation 
has been investigated in HIV-negative men and women at doses of 150mg, 300mg, 600mg 
and 1200mg given intramuscularly (IM).(58) In men, at the 600mg dose the geometric mean 
(90% CI) rectal tissue:plasma ratio was 0.98(0.85-1.11) on day 7 while in women, the 
geometric mean (90% CI) vaginal tissue:plasma ratio was 0.72(0.4-1.05) on day 7. The 
authors concluded that the compartmental rilpivirine concentrations were proportional to the 
dose administered. A planned phase II study of the long acting injectable formulation of 
rilpivirine TMC278LA will evaluate the 1200 mg dose for chemoprophylaxis.(59)
Dapivirine is also being developed as a topical microbicide formulated in intravaginal rings 
(IVRs), gels and films. In 24 HIV-negative women, concentrations attained in the lower 
female genital tract 28 days after placement of an IVR were 5 log units higher than 
maximum concentrations achieved in the plasma over the 28 day period.(60) Further, there 
was a linear relationship (p=0.0157) between tissue concentration and protective effect.(61) 
The FAME-02 study in 60 HIV-negative women that compared the PK/PD and safety of gel 
(0.05%) and film (1.25mg) formulations of dapivirine found that both formulations achieved 
low and comparable plasma concentrations (302.47 pg/mL for gel compared to 227.13 
pg/mL for film). However tissue concentrations of dapivirine from the film were four times 
lower than concentrations from the gel, and this correlated with greater infectivity in the ex-
vivo challenge experiments with vaginal and cervical biopsies.(62) These novel 
formulations may be used to help achieve protective mucosal drug exposure with decreased 
systemic exposure and reduced dosing frequency.
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4.3 Integrase Inhibitors (INSTIs)
INSTIs represent the newest class of antiretrovirals with the first agent in class, raltegravir, 
approved in 2007. This was followed by elvitegravir in 2012 and dolutegravir in 2013. As a 
class, these agents are potent, well tolerated, and exhibit lower drug interaction potential 
than protease inhibitors (PIs) and NNRTIs. Glucuronidation is the primary route of 
metabolism for raltegravir and dolutegravir, while elvitegravir is primarily metabolized by 
the CYP450 enzyme system. For this reason some have been proposed as second generation 
PrEP strategies. To date, raltegravir and dolutegravir have data available on drug penetration 
into mucosal tissues.
Raltegravir exhibits the lowest degree of protein binding (83%) within this class.(63) Data in 
HIV-negative and HIV-infected premenopausal women have shown median (IQR) 
raltegravir cervicovaginal fluid:blood plasma steady state AUC0-12hr ratios of 0.93 (0.4, 1.7) 
and 4.4 (1.5, 7.2), respectively.(64) The DIVA trial investigated raltegravir trough 
concentrations in the blood plasma and cervicovaginal fluid of 14 HIV infected women.(65) 
The median (IQR) cervicovaginal fluid:blood plasma ratio was 2.3 (1.4-4.1). Of the trial's 
three study subjects with bacterial vaginosis, two exhibited cervicovaginal fluid:blood 
plasma ratios that were 4 to 16-fold greater than the median, suggesting that inflammation 
may increase raltegravir exposure in the female genital tract. Raltegravir is a substrate for 
the MDR1 efflux transporter (66) which is highly expressed in the female genital tract and 
generally attenuated in the presence of inflammatory mediators, therefore accumulation of 
raltegravir in inflamed female genital mucosal tissue is biologically plausible.
Conversely, dolutegravir exposure in female genital tract tissues and cervicovaginal fluid 
was found to be <10% of blood plasma.(67) Dolutegravir is much more extensively protein 
bound (≥98%) than raltegravir which could potentially explain this low degree of 
distribution.(68) Despite this, 94% of samples collected from the female genital tract were 
above dolutegravir's protein adjusted IC90 of 64ng/mL(67). Since cervicovaginal fluid 
concentrations of AAG (the major serum protein responsible for binding dolutegravir) are 
approximately 1% of blood plasma(17), dolutegravir exposure in the female genital tract 
may be sufficient despite the compound's poor penetrative capacity.
In the lower gastrointestinal tract, raltegravir was found to rapidly distribute after a single 
dose, reaching concentrations in the terminal ileum which exceeded plasma concentrations 
within 2 hours and peak concentrations within 4 hours.(69) After a single 400mg dose, the 
highest concentrations were achieved in the terminal ileum followed by the splenic flexure, 
and the rectal tissue (AUCcomposite = 594, 258, and 143ng*hr*mL−1, respectively). Under 
steady-state conditions with 400mg dosed twice daily, the splenic flexure exhibited the 
highest exposure with an AUCcomposite of 2240ng*hr*mL−1 where the AUCcomposite was 
788ng*hr*mL−1 in both the terminal ileum and the rectum. A single dose, dose ranging 
pharmacokinetic study investigating 200 to 800mg or raltegravir in healthy women found 
exposure in the lower gastrointestinal tract is approximately 25-fold greater than in the 
female genital tract, and colorectal exposure is similar between women and men.(70) 
Dolutegravir was found to poorly distribute to the rectal tissue of healthy males, with a 
median AUCcomposite penetration ratio of 0.17.(40) Despite low rectal exposure relative to 
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blood plasma, 100% of concentrations from the lower gastrointestinal mucosa were above 
the protein adjusted IC90.(40)
Cabotegravir is an investigational INSTI, which has a similar chemical structure to 
dolutegravir.(71) It is formulated as a long acting injectable nanoparticle suspension for 
intramuscular administration in HIV treatment and prevention.(71) Cabotegravir exhibits 
plasma pharmacokinetics which support 4 and 8 week dosing intervals. Both dosing 
intervals are currently under investigation in phase IIb studies for HIV treatment.(72) 
Similar to dolutegravir, a 400mg IM dose of cabotegravir was found to exhibit cervical/
vaginal and colorectal penetration ratios of 0.16-0.19 and ≤0.08, respectively, 2-8 weeks 
after a single injection.(73) While median rectal tissue concentrations at 4 and 12 weeks 
following a 400mg split IM injection were below the protein adjusted IC90 (16.6ng/mL), the 
median concentration in cervical and vaginal tissue was above this value at the week 4 and 
12 visit, respectively.(73) Recently, Radzio et al. demonstrated 100% protection in 
macaques vaginally challenged with biweekly SHIV for up to 20 weeks after the last of 3 
monthly 50mg/kg injections.(74) This study found low penetration to the mucosal 
compartment similar to humans with cervicovaginal and rectal fluid:plasma AUC ratios of 
0.16 and 0.38, respectively. Andrews et al. also demonstrated 100% protection in macaques 
that were rectally challenged with weekly SHIV for up to 20 weeks following two monthly 
50mg/kg injections and 5 weeks following a single injection.(75) In the single injection 
study, plasma concentration ≥1× PAIC90 correlated with 97% protection whereas plasma 
concentrations <PAIC90 resulted in 75% protection. Following plasma pharmacokinetic 
modeling and simulation, the group determined that an 800mg split IM dose administered 
every 3 months would be carried forward into clinical PrEP trials.(76)
4.4 Protease Inhibitors (PIs)
PIs inhibit the protease enzyme responsible for post translational cleavage of viral proteins. 
These compounds generally have large molecular weights and exhibit extensive protein 
binding and hepatic biotransformation via the CYP450 system.(77) These pharmacologic 
complexities, coupled with their post integration mechanism of action, have resulted in this 
class being generally overlooked for HIV prevention strategies. Therefore the literature 
regarding protease inhibitors' mucosal tissue pharmacokinetics is limited. Investigation of 
the cervicovaginal secretions of HIV infected women receiving stable HAART revealed that 
indinavir and darunavir exhibit the highest degree of female genital tract penetration among 
the protease inhibitors. Median (range) trough cervicovaginal fluid:blood plasma ratios of 
3.8 (0.99-10) and 4.64(0.8-26.93) have been reported for indinavir.(52, 78) For darunavir the 
median (IQR) AUC cervicovaginal:blood plasma ratio is 1.5 (1.0-1.6).(79) Amprenavir, 
ritonavir, atazanavir, lopinavir, and saquinavir (listed in order of rank from highest to 
lowest) all exhibit ratios of <1.(43, 52, 78) Of all the protease inhibitors indinavir exhibits 
the lowest degree of protein binding (54-70%), which possibly accounts for its high 
penetrative capacity.(80)
Only darunavir and ritonavir have been studied in the lower gastrointestinal mucosal tissues 
of HIV-negative men. Following a single dose, darunavir and ritonavir were rapidly detected 
(within 1 hour), reaching peak concentrations by 5 hours.(57) Under steady state conditions, 
Cottrell et al. Page 10













the rectal tissue:blood plasma AUC0-12hour ratio was ∼2.7 for darunavir and 27 for ritonavir.
(57)
The potency and high genetic barrier to resistance exhibited by protease inhibitors, make 
them favorable HIV treatment options. It has been previously shown that viral replication 
can persist in lymphoid tissue despite effective HAART therapy and that this persistence 
may correlate with decreased antiretroviral exposure.(81, 82) Since gut associated lymphoid 
tissue may serve as a potential reservoir of persistent viral replication in patients, tissue 
penetration could be a theoretical consideration in designing ARV regimens, similar to the 
CNS Penetration-Effectiveness (CPE) score proposed by the CHARTER Group.(83) 
However, unlike the CPE score, increased mucosal tissue penetration have not yet been 
linked to more favorable outcomes.
4.5 Entry inhibitors
Maraviroc is a chemokine receptor antagonist that prevents the virus from binding to the 
CCR-5 co-receptor on CD4+ T cells. Currently, it is the only clinically approved agent in its 
class. Maraviroc concentrates in the female genital tract.(19) In a study of 12 healthy 
volunteer women, AUC0-12h in cervicovaginal fluid was 3645 (1785–7505) ng*h*mL−1 
after a single 300 mg dose. After twice daily dosing for seven days, cervicovaginal fluid and 
vaginal tissue AUC0-12h was 7500 (3078–9090) ng*h*mL−1 and 4857 ng*h*mL−1, 
respectively.(19) High concentrations of maraviroc were found in the rectal tissue of HIV-
negative men both after single and multiple dosing at 300 mg doses.(84) Composite AUC 
ratios in the rectal tissue were 7.5 (single dose) to 26-fold (multiple dose) higher than blood 
plasma. The maraviroc accumulation ratio from single to multiple dosing in plasma and 
rectal tissue was 1.4 and 4.9, respectively, which suggests an additional mechanism of 
increased drug exposure in colorectal tissue. Since maraviroc's bioavailability is 23%(85), it 
is likely that local, luminal concentrations of maraviroc passing through the gastrointestinal 
tract are contributing to increased rectal tissue exposure. A recent phase 1, single-dose 
pharmacokinetic study also found a 10-fold higher exposure of maraviroc in rectal tissue as 
compared to cervicovaginal tissue.(70) Since maraviroc is a substrate for the efflux 
transporter MDR1, and this transporter demonstrates 5.5-fold higher mRNA expression in 
vaginal tissue (27), it may be responsible for the differential penetration between female 
genital tract tissue and colorectal tissue.
Maraviroc has also been incorporated into silicone elastomer vaginal rings for use as a 
topical microbicide in combination with dapivirine. This system that contains 100 mg 
maraviroc and 25 mg dapivirine was recently studied as part of a phase I clinical trial in 24 
HIV-negative women who wore the ring for 28 days. While dapivirine was detected in all 24 
cervical tissue samples (mean concentration of 1.6μg/mL), only 4 of 24 (16.67%) samples 
exhibited detectable concentrations of maraviroc.(61) This low release of maraviroc has 
resulted in re-formulation efforts, which are ongoing.(86)
5. Expert Opinion
Antiretroviral based prevention has previously demonstrated a high level of effectiveness in 
the context of mother-to-child transmission with nevirapine and zidovudine.(87) These 
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prevention approaches have been explored for their potential to offer efficacious, relatively 
discreet, user-controlled HIV prevention options to adults at high risk of HIV acquisition. 
Because HIV is primarily transmitted through mucosal fluids, and early infection occurs 
within mucosal tissues, characterizing pharmacokinetic behavior within these peripheral 
compartments is important for optimizing PrEP and TasP initiatives.
Given that the PrEP end user population is healthy adults, the ideal PrEP agent would have 
minimal side effects, a low drug interaction potential, and allow for infrequent or as-needed 
dosing. Oral dosing formulations for two NRTIs (tenofovir and emtricitabine), raltegravir 
and maraviroc all exhibit excellent capacity to penetrate into mucosal tissue with 
concentrations that either match or exceed blood plasma concentrations with single and 
multiple doses. These agents' penetrative ability coupled with relatively uncomplicated drug 
interaction and side effect profiles make them good candidates for PrEP. Also, alternative 
antiretroviral formulations, such as 1% tenofovir gel and the dapivirine ring, are designed to 
achieve high local tissue concentrations and low plasma exposure. These formulations offer 
intermittent or reduced frequency dosing options.
In general NNRTIs and PIs exhibit a low degree of penetration into tissue. While 
complicated drug interaction and adverse events profiles impede their use in PrEP, NNRTIs 
and PIs are widely used in HIV treatment. Drugs within these classes that demonstrate 
extensive penetration, like darunavir and etravirine, may provide some theoretical benefit to 
TasP approaches.
Lastly, the pharmacokinetic data demonstrating preferential distribution of certain 
antiretrovirals, like tenofovir, into the colorectal mucosa relative to the female genital 
mucosa strongly support the notion that the site of HIV exposure determines the degree of 
protection achieved by a PrEP regimen. This knowledge can be used to tailor PrEP strategies 
to the target end user. For instance future PrEP trials or marketing initiatives directed at 
women are more likely to benefit from rigorous adherence counseling and intervention 
given that the female genital tract exhibits a smaller pharmacokinetic buffer for missed 
doses. In contrast, investigations of intermittent Truvada® PrEP regimens for MSM is 
strongly supported by pharmacokinetic data. This concept was recently confirmed with the 
success of the IPERGAY trial, which investigated an intermittent dosing regimen before and 
after sex in MSM.(88)
Understanding the pharmacokinetics of antiretrovirals in the mucosal tissue represents only 
one aspect of optimizing antiretroviral use for HIV prevention. A thorough characterization 
of target concentrations required for protection and subsequently well-defined PK/PD 
relationships represents another important aspect of defining dosing strategies.(89) 
However, this has been inconsistently defined for antiretroviral prevention. One reason is 
the lack of consensus on appropriate preclinical models of infection for defining 
concentration response relationships. The limitations of in vitro and ex vivo models have 
been reviewed in detail elsewhere (90, 91), but include a lack of tissue architecture and 
relevant microenvironment, and the use of clinically appropriate virus and viral inoculum.
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Using clinical trial data from the CAPRISA004 study Karim et al. determined that women 
with cervicovaginal fluid tenofovir concentrations of >1000ng/mL exhibited a higher degree 
of protection (74%) than those with <1000ng/mL (14%).(92) Whether this target tenofovir 
concentration is also required for oral dosing strategies remains to be determined. Using data 
generated from the iPrEx study, Anderson et al. have proposed an EC90 concentration of 16 
fmol TFVdp/million PBMCs with oral Truvada® dosing in MSM.(93) However the 
concentrations used in this approach were derived from cryopreserved PBMCs which can 
lose up to 60% of TFVdp compared to traditional methods of cell isolation.(93, 94) 
Therefore, this estimate likely underestimates the true effective concentration of TFVdp in 
PBMCs that results in colorectal tissue protection. Given the pharmacokinetic differences 
between the female genital and lower gastrointestinal tracts, it's also unlikely that these 
results can be extrapolated to a female population.
One recent preclinical and clinical approach to determine the concentration vs response 
relationship for tenofovir and emtricitabine measured intracellular metabolites (TFVdp and 
FTCtp) relative to competitive natural substrates of reverse transcriptase (deoxyadenosine 
triphosphate; dATP and deoxycytidine triphosphate; dCTP).(95, 96) When combining these 
data into a mathematical model to simulate mucosal tissue exposure achieved by various 
doing strategies, 80% protection from HIV transmission was predicted for the female genital 
tract with daily Truvada® dosing and 90% protection was predicted for the lower 
gastrointestinal tract with 2 doses per week. These predictions are in close agreement with 
observational data from clinical trials.(10, 11)
In the absence of well-defined efficacy target concentrations, important inferences can still 
be made from the available mucosal tissue pharmacokinetic data. Although it's not clear 
which anatomical locations should be preferentially targeted to reduce HIV transmission (eg 
mucosal tissues, regional lymph nodes), antiretrovirals with mucosal tissue concentrations 
above the viral IC90 may be considered preferable for both PrEP and TasP. Since the extent 
of antiretroviral mucosal tissue penetration is unpredictable, tissue pharmacokinetic data are 
essential for optimizing dosing strategies for HIV prevention.
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1. Antiretroviral distribution to mucosal tissues is governed by a number of 
complex factors including lipophilicity, protein binding, and active transport.
2. The degree of antiretroviral mucosal tissue distribution is highly variable 
between and within antiretroviral therapeutic drug classes (Figure 1).
3. As a drug class, nucleoside reverse transcriptase inhibitors (NRTIs) achieve 
higher exposure in the mucosal tissues compared to non-nucleoside reverse 
transcriptase (NNRTIs) and protease inhibitors (PIs) (Figure 1).
4. In general antiretrovirals exhibit higher exposure in the lower gastrointestinal 
mucosal tissue compared to the female genital mucosal tissue.
5. This article elucidates some important knowledge gaps in the field of mucosal 
tissue pharmacokinetics which warrant further study to better characterize, 
including: 1) drug transporters and their regulation in mucosal tissues 2) the 
effect of hormonal regulation and inflammation on mucosal tissue distribution 
and 3) mucosal pharmacodynamic targets for HIV prevention.
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Figure 1. Antiretroviral Female Genital and Lower Gastrointestinal Tract Penetration Ratios
This figure reports the mucosal tissue or fluid:blood plasma area under the concentration 
time curve (AUC) ratios for 22 antiretrovirals stratified by class. Both single dose (open 
symbols) and steady state (closed symbols) are reported when available. The line of unity 
(mucosal tissue/fluid AUC=blood plasma AUC) is denoted by the solid reference line. In 
general penetration ratios tend to be higher in the lower gastrointestinal tract for most 
antiretrovirals. As a class nucleoside reverse transcriptase inhibitors (NRTIs) and the entry 
inhibitor (EI), maraviroc(MVC), tend to demonstrate a high degree of penetration (>1) into 
the female genital and lower gastrointestinal tracts whereas non nucleoside reverse 
transcriptase inhibitors (NNRTIS) and protease inhibitors (PIs) tend to exhibit low 
penetration (<1). ABC=abacavir, ddI=didanosine, FTC=emtricitabine, 3TC=lamivudine, 
d4T=stavudine, TFV=tenofovir, AZT=Zidovudine, DTG=dolutegravir, RTG=raltegravir, 
DLV=delavirdine, EFV=efavirenz, ETR=etravirine, NVP=nevirapine, APV=amprenavir, 
ATV=atazanavir, DRV=darunavir, FPV=fosamprenavir, IDV=indinavir, LPV=lopinavir, 
NFV=nelfinavir, RTV=ritonavir, INSTIs=integrase strand transfer inhibitors.
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Table 1
Antiretroviral Drugs Are Substrates for Drug Transporters (24, 68)
Class Antiretroviral Drug Transporter
NRTIs
Abacavir P-gp BCRP MRP4
Emtricitabine MRP1
Lamivudine BCRP OCT1 OCT2
Tenofovir DF P-gp





Atazanavir P-gp MRP1 MRP2
Darunavir P-gp OATP1A2 OATP1B1
Lopinavir P-gp MRP1 MRP2 OATP1A2 OATP1B1
EIs Maraviroc P-gp
BCRP=breast cancer resistance protein, DF=disoproxil fumarate, EIs=Entry inhibitors, INSTIs=integrase strand transfer inhibitors, 
NRTIs=nucleoside reverse transcriptase inhibitors, PIs=protease inhibitors
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